U.S. Patent Application Serial No. 10/822,860 Amendment filed January 11, 2008 Reply to OA dated November 15, 2007

AMENDMENT TO THE DRAWINGS:

Please amend Figure 1, by replacing drawing sheet 1 with the attached replacement drawing sheet. An annotated drawing sheet is also provided, indicating the changes. The amendment to the drawings is explained in the Remarks section, below.

U.S. Patent Application Serial No. 10/822,860 Amendment filed January 11, 2008 Reply to OA dated November 15, 2007

AMENDMENT TO THE SEQUENCE LISTING

In accordance with 37 CFR 1.825, the Sequence Listing is amended by submission of the attached substitute sheets of the paper copy, a computer readable form (floppy disk), and a statement verifying that the amended Sequence Listing contains no new matter.

REMARKS

Claims 15-18 are pending in this application. No amendment is made to the claims in this

Amendment. The Specification, the Sequence Listing and the Drawings are amended.

The applicants respectfully submit that no new matter has been added. It is believed that this

Amendment is fully responsive to the Office Action dated November 15, 2007.

The specification is objected to. (Office action paragraph no. 2)

The specification is objected to for disclosure of amino acid sequences without a SEQ ID

NO:, for the last four amino acids of Smad2 and Smad3 in Fig. 1.

The objection is overcome by the amendment to the Sequence Listing. In the amended

Sequence Listing, SEQ ID NO: 5, for SSMS, and SEQ ID NO: 6, for SSVS, have been added. These

are the sequences shown in Fig. 1. No new matter is added by this amendment, since the sequences

were already disclosed in Fig. 1.

Fig. 1 has also been correspondingly amended to reference these SEQ ID NO's where these

sequences occur in the figure.

The disclosure is objected to. (Office action paragraph no. 3)

The disclosure is objected to because the specification refers to Table 8 on page 39 and there

is no Table 8. The specification is amended here to change "Table 8" to -- Fig. 8 --, correcting the

typographical error.

-5-

U.S. Patent Application Serial No. 10/822,860 Amendment filed January 11, 2008 Reply to OA dated November 15, 2007

If, for any reason, it is felt that this application is not now in condition for allowance, the Examiner is requested to contact the applicant's undersigned agent at the telephone number indicated below to arrange for an interview to expedite the disposition of this case.

In the event that this paper is not timely filed, the applicant respectfully petitions for an appropriate extension of time. Please charge any fees for such an extension of time and any other fees which may be due with respect to this paper, to Deposit Account No. 01-2340.

Respectfully submitted,

KRATZ, QUINTOS & HANSON, LLP

Daniel A. Geselowitz, Ph.D.

Agent for Applicants Reg. No. 42,573

DAG/xl

Atty. Docket No. **040176** Suite 400 1420 K Street, N.W. Washington, D.C. 20005 (202) 659-2930

23850

PATENT & TRADEMARK OFFICE

Enclosures: Replacement Sheet of Drawings (Sheet 1)

Annotated Sheet of Drawings showing changes

Amended Sequence Listing

Statement Verifying Nucleotide and/or Amino Acid Sequence Submission

Computer-Readable form of Sequence Listing (Floppy Disk)

H:\HOME\XLU\040\040176\Amendment in re Quayle Action of 11-15-07




FIG. 2A

EPSM

3S-A

WT

Flag-Smad2

	LIGH-B,	 	 	TO COLOR
	IB: αpSmad2L			MAPK - dependent - pSmad2 - lgH
IP; α Flag	α pSmad2C			TBRI- dependent pSmad2 - IgH
	α Flag			- Smag2